Nimble Closes a €1 Million Round Led by Grow Ventures and Namarel Ventures

Nimble raises capital. The Spanish company that creates a microwave monitor for cardiac stents has closed a round of one million euros led by Grow Ventures Partners and Namarel Ventures, according to Oriol Iborra, CEO of Nimble.

The Catalan company was looking for €850,000 but has ended up exceeding the figure. The Inveniam Group, which has acted as a syndicate of different business angels  (Olivier Resnik and Jorge Bensadon), has also participated in the financing round.

Namarel Ventures is one of the investment vehicles of Xavier Rubiralta, a member of the family that owns the Catalan company Werfen. With the resources obtained, Nimble intends to advance in the development of its technology against heart disease in order to be able to commercialize it in the future.

If you want to find more details about the new cardiac stents that the company Nimble is testing and the new fundraising round it just closed, download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the latest financial news of the day, so they can stay on top of the market.

Nimble intends to conclude this year the preclinical phase of trials with pigs

Nimble is a spin-off of the Institut Germans Trias i Pujol (Igtp) of Badalona (Barcelona), the University of Barcelona (UB), and the Polytechnic University of Catalonia (UPC). With its technology,  the company aims to prevent possible heart disease in a non-invasive way. This will make it possible to implement early treatments and avoid serious complications, as well as to identify and optimize medical procedures.

Nimble will now complete the preclinical testing phase, which it will carry out with pigs, to later carry out the first clinical trial at the Germans Trias i Pujol Hospital, presumably in 2024, according to Iborra. Likewise, the company also plans to hire staff thanks to the economic injection. The start-up plans to start marketing its devices in 2025.

It is the first round of private financing that Nimble has obtained, although the company has received public investment -half a million euros- thanks to  CaixaImpulse, FIS, the TV3 Marathon, and the Catalan Society Award.

Beyond Oriol Iborra, the founding team is completed by Susana Amorós, Carolina Gàlvez, Oriol Rodríguez, and Antoni Bayés, in addition to including researchers Joan Manel O’Callaghan, Lluís Jofre, and Jordi Romeu, from the UPC, and Javier Tejada, from the ub.

70% of the capital rests with the founding team of Nimble 

With this round, most of the company’s capital falls into the hands of the founding team, which controls 70%, while the remaining 30% is distributed among new investors, according to Iborra.

Stents are medical devices capable of restoring the flow of blood or other fluids. These cannulas are used to treat cardiovascular diseases and thus prevent both myocardial infarction and treat symptoms after it. 

The business opportunity comes from the obsolescence of stents, since once implanted, they can become blocked or damaged. Even so, the symptoms in the patient usually appear when these utensils have already lost 90% of their functionality. “We want our technology to reach primary care,” adds the CEO of Nimble.

__

(Featured image by jesse orrico via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.